BioLineRx (BLRX) Enterprise Value (2012 - 2025)

BioLineRx's Enterprise Value history runs 14 years deep, the most recent figure standing at -$15.7 million for Q4 2025.

• In Q4 2025, Enterprise Value rose 19.6% year-over-year to -$15.7 million; the TTM figure through Dec 2025 stood at -$15.7 million (up 19.6% YoY), while the FY2025 annual figure was -$15.7 million, up 19.6% from the prior year.
• Enterprise Value was -$15.7 million for Q4 2025 at BioLineRx, up from -$25.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$15.7 million in Q4 2025 to a low of -$65.6 million in Q2 2021.
• Historically, Enterprise Value has averaged -$40.0 million across 5 years, with a median of -$38.8 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Enterprise Value tumbled 198.67% in 2021, then jumped 54.65% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$57.1 million in 2021, then gained by 10.59% to -$51.1 million in 2022, then climbed by 15.83% to -$43.0 million in 2023, then surged by 54.5% to -$19.6 million in 2024, then rose by 19.6% to -$15.7 million in 2025.
• The last three Enterprise Value figures came in at -$15.7 million (Q4 2025), -$25.2 million (Q3 2025), and -$31.4 million (Q2 2025), per Business Quant data.